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Abstract
Objectives: Regulatory T cells (Treg) increase in the context of HIV infection and pregnancy. We studied Treg
subpopulations in HIV-infected and uninfected women during pregnancy and their relationship with inflammation,
activation and cell-mediated immunity (CMI).
Design and Methods: Blood obtained from 20 HIV-infected and 18 uninfected women during early and late gestation was
used to measure Treg and activated T cells (Tact) by flow cytometry; plasma cytokines and inflammatory markers by ELISA
and chemoluminescence; and CMI against varicella-zoster virus (VZV) by lymphocyte proliferation.
Results and Conclusions: Compared with uninfected women, HIV-infected participants had higher frequencies of Treg
subpopulations in early pregnancy, including CD4+CD25+FoxP3+%, CD8+CD25+FoxP3+%, CD4+TGFb+% and CD4+IL10+%.
In contrast, Treg frequencies were lower during late pregnancy in HIV-infected compared with uninfected women, including
CD8+TGFb+%, CD4+CTLA4+% and CD8+CTLA4+%. VZV-CMI, which was lower in HIV-infected compared with uninfected
pregnant women, was inversely correlated with CD4+FoxP3+%, CD8+FoxP3+% and CD8+TGFb+% in HIV-infected, but not in
uninfected pregnant women. b2-microglobulin, neopterin, IL1, IL4, IL8, IL10, IFNc and TNFA plasma concentrations as well as
Tact were higher in HIV-infected compared with uninfected women throughout pregnancy. In HIV-infected, but not in
uninfected women, inflammatory, Th1, Th2 and regulatory cytokines increased with higher Treg%, suggesting that
inflammation and regulation have a common pathophysiologic origin in the context of HIV infection. In HIV-infected and
more commonly in uninfected pregnant women, higher Treg% correlated with lower Tact%. We conclude that Treg have
different dynamics during pregnancy in HIV-infected and uninfected women. Higher levels of inflammatory cytokines and
lower Treg% during late pregnancy in HIV-infected women may contribute to their increased incidence of maternal-fetal
morbidity.
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Introduction
There is growing evidence that regulatory T cells (Treg) strongly
influence adaptive immune responses. The role of Treg in down-
modulating inflammation and consequently preventing morbidity is
clearly established in the context of autoimmune disorders and
transplantation [1,2]. Evidence has been accumulating to support a
similar down-modulatory effect of Treg in the context of infectious
and neoplastic disorders, but with undesired clinical consequences,
such as establishing permissive conditions for chronic infections and
tumor growth [3,4,5]. The behavior of Treg and their role in the
context of HIV infection has been debated. Some studies presented
evidence that increased proportions of Treg were present in HIV-
infected individuals and favored HIV replication [6,7,8,9,10,11,12],
which is typically associated with increased inflammation and
activation. Other studies suggested that Treg were decreased in
HIV-infected individuals, which contributed to the persistent
immune activation associated with HIV infection and created
conditions for the development of immune reconstitution syn-
dromes [13,14,15]. As immune modulating agents progressively
enter the therapeutic arena, it is important to establish the role of
Treg in the pathogenesis of HIV infection.
T cell activation is a hallmark of HIV pathogenesis [16,17,18].
An excess of both CD4+ and CD8+ activated T cells (Tact) are
present in the peripheral blood of HIV-infected individuals and
directly or indirectly contribute to the loss of CD4+ T cells [7,19].
Furthermore, in HAART recipients, increased inflammatory
activity has been associated with cardiovascular, hepatic and
renal disorders [20,21,22,23,24], which, together with non-AIDS-
related malignancies, account for a growing proportion of
morbidity and mortality of HIV-infected individuals in the era
of HAART [25,26].
Pregnancy is associated with increased inflammatory biomark-
ers and with higher Treg proportions [2,27,28,29,30,31]. Preg-
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28172nancy does not appear to accelerate HIV disease progression or
increase the risk of death of HIV-infected women [32]. However,
pregnancy has been associated with increased transmission and
acquisition of HIV [33], which would be consistent with the
generalized immunosuppression as well as with increased
activation and immune-regulatory activity during pregnancy
[2,34,35]. Previous studies showed that inflammatory biomarkers
and Tact are higher in HIV-infected pregnant women compared
with uninfected pregnant women [27,28,34]. The level of
inflammatory cytokines may affect the outcome of pregnancy by
increasing the risk of premature delivery and of other pregnancy-
specific complications [36,37,38,39,40,41,42].
The goal of this study was to define the dynamics of Treg in
HIV-infected pregnant women by comparison with uninfected
women and to determine the relationship of Treg with cell-
mediated immunity (CMI), inflammatory factors and T cell
activation during pregnancy.
Methods
Study Design
This was a prospective study performed at the Children’s
Human Immunodeficiency Program at The Children’s Hospital in
Denver and University of Colorado Hospital. Subjects were HIV-
infected and uninfected pregnant women who provided written
consent to participate in this study approved by the Colorado
Multiple Institution Review Board. All women were seropositive
for varicella-zoster virus (VZV). Blood was obtained during the 2
nd
and 3
rd trimesters of pregnancy. Laboratory studies included
CD4+ and CD8+ cell enumeration, inflammatory biomarkers,
Treg, Tact and VZV -specific CMI and serology in all participants
and HIV plasma RNA in HIV-infected women.
Plasma cytokines and inflammatory biomarkers
IL1, IL4, IL6, IL8, IL10, IFNc and TNFA were measured with
the chemoluminescence commercial kit Quansys [Quansys
Biosciences; limit of detection (LOD) of 0.87, 1.78, 0.21, 0.22,
0.25 and 0.73 pg/mL respectively). C-Reactive Protein (CRP),
b2-microglobulin, CTLA-4 and neopterin were measured with the
following kits: Quantikine (R & D Systems; LOD=0.01 ng/mL),
b2-Microglobulin ELISA Kit (Immundiagnostik AG; LOD=
0.1 mg/L), CTLA-4 ELISA Kit (Invitrogen; LOD=0.2 ng/mL)
and Neopterin ELISA (IBL, Inc.; LOD=0.7 nmol/L). All assays
were performed according to the manufacturers’ instructions, in
duplicate wells. Results were considered valid if replicates differed
by ,2-fold and if positive and negative controls were within the
ranges specified by each kit.
CMI Assays
Peripheral blood mononuclear cells (PBMC) from heparinized
blood, separated by ficoll/hystopaque density gradient centrifu-
gation (Sigma Chemical Company), were cryopreserved as
previously described [43].
LPA was performed as previously described [43]. Stimulation
medium consisted of RPMI 1640 with glutamine (Gibco), 10%
human AB serum (NABI) and 1% antibiotics (Gibco). PBMC (10
5
cells/well) were added to quadruplicate wells containing VZV cell
lysate, mock-infected control lysate and pokeweed mitogen (Sigma)
at 10 mg/mL. After six days at 37uCi n5 %C O 2 atmosphere, cells
were pulsed with 20 mCi/mL
3H-thymidine and their DNA was
harvested 6 h later onto filter mats (Perkin Elmer). Radioactivity
on the filters was counted on a microplate scintillation counter
(Packard). Assays were considered valid if the pokeweed mitogen-
stimulated wells had 10-fold higher counts-per-minute (cpm) than
the medium control. Results were expressed as median cpm in
VZV-stimulated wells minus median cpm in mock-stimulated
control wells.
Flow cytometry. The T-cell phenotypes were assessed by
flow cytometry using freshly thawed PBMC. Cells were stained
using monoclonal antibodies against the following molecules: CD3
(BD Biosciences), CD4 (Beckman Coulter), IL-10 (eBioscience),
TGFb (Cedarlane), FoxP3 (eBioscience), CD25 (BD Biosciences),
CTLA4 (BD Biosciences),CD38 (BD Biosciences), and HLADR
(BD Biosciences). Total T cells and subpopulations were counted
on Guava easyCyte 8HT (Millipore) and analyzed with FlowJo
(Treestar). Subpopulations were expressed as percentages of the
parent CD4+ or CD8+ T cell populations.
Statistical analysis was performed using Prism5 and InStat
software (GraphPad). Parametric tests were used when the
distribution of the data was normal. Nonparametric tests were
used when the distribution was not normal even after log
transformation. Significance was defined by a p value ,0.05.
Results
Demographics
The study enrolled 20 HIV-infected and 18 uninfected pregnant
women with mean6SD gestational age of 1967 and 1766 weeks,
respectively (Table 1). There were more black women among the
HIV-infected compared with the uninfected participants (6 vs. 0),
reflecting the characteristics of the HIV epidemic in the USA.
However, this difference did not reach statistical significance
(p=0.06, Chi square). HIV-infected women also tended to be
younger than the uninfected women (p=0.06) and had signifi-
cantly lower CD4+ and higher CD8+ cell counts (p#0.01). All
HIV-infected women received HAART for $24 days before the
first study visit, including 4 who were on HAART before
pregnancy. The median (range) of the plasma HIV viral load of
the HIV-infected participants decreased, but not significantly,
between the entry and the late pregnancy visits: 74 (,20; 61,100)
and ,20 (,20; 4,130) RNA copies/ml, respectively, p=0.20 (1-
tail paired T test).
Table 1. Baseline Characteristics of Study Participants.
Characteristic HIV-infected Uninfected P value
Numbers 20 18 n.a.
Years of age (mean6S.D.) 26652 9 66 0.06*
Race
White 11 14 0.06
#
Black 6 0
Hispanic 3 3
Asian 0 1
Weeks gestation (mean6S.D.) 19671 7 66 0.207*
CD4 cells/ml (mean6S.D.) 4806217 9716220 ,0.0001*
CD8 cells/ml (mean6S.D.) 7746437 4476214 0.01*
Plasma HIV RNA c/ml (median;
range)
74; ,20–61,100 n.a. n.a.
Days of HAART (median; range) 41; 24–337 n.a. n.a.
*Unpaired T test.
# Chi-square.
Bold facing indicates significant differences.
doi:10.1371/journal.pone.0028172.t001
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Treg were measured at entry (early pregnancy) and during the
3
rd trimester (late pregnancy). The third trimester visit occurred at
mean6SEM of 3366 weeks gestation in both groups of
participants. Treg were characterized by the expression of FoxP3,
co-expression of FoxP3 and CD25, CTLA4, IL10 and TGFb
(Fig. 1). The last 3 markers were chosen for their ability to provide
some information on the Treg mechanisms of action.
In early pregnancy, Treg frequencies were higher or similar in
HIV-infected compared with uninfected women. Significant or
marginally significant differences were observed for
CD4+CD25+FoxP3+% (p=0.1), CD8+CD25+FoxP3+%
(p=0.03), CD4+TGFb+% (p=0.03) and CD4+IL10+%
(p=0.04). In late pregnancy, CD4+IL10+% tended to continue
higher in HIV-infected compared with uninfected women
(p=0.09). In contrast, other Treg subpopulations were lower in
HIV-infected women, including CD8+TGFb+% (p=0.02),
CD4+CTLA4+% (p=0.005) and CD8+CTLA4+% (p=0.006).
In HIV-infected women, there were no significant changes in any
of the Treg subpopulations between early and late pregnancy.
However, in uninfected women, CD8+CD25+FoxP3+% and
CD4+TGFb+% tended to increase from early to late time points
(p of 0.07 and 0.1, respectively).
Functional CMI during pregnancy and post-partum in
HIV-infected and uninfected women
VZV-specific CMI was measured in this study. All HIV-infected
and uninfected participants in this study were VZV-seropositive.
HIV-infected women had significantly lower VZV-CMI compared
with those of uninfected women during early and late pregnancy (p
of 0.0002 and 0.0007, respectively; Fig. 2). There were no
significant changes in VZV-CMI with advancement of pregnancy
in either group.
Plasma cytokines and inflammatory factors in early and
late gestation in HIV-infected and uninfected women
We compared the plasma concentrations of CRP, neopterin,
b2microglobulin, CTLA4, IL1, IL4, IL6, IL8, IL10, IFNc and
TNFa (Fig. 3). All cytokines and inflammatory factors with the
exception of CRP, IL6 and soluble CTLA4 showed significantly
higher plasma concentrations in HIV-infected compared with
uninfected women both in early and late gestation (p,0.0001 to
0.02). In contrast, soluble CTLA4 concentrations were signifi-
cantly lower in HIV-infected women compared with uninfected
controls in early and late pregnancy (p=0.0001 and ,0.0001,
respectively). CRP and IL6 levels (data not depicted) were similar
in HIV-infected and uninfected women in early (mean 6SEM of
1.660.1 vs. 1.060.1 ng/ml and 49626 vs. 26.3610 pg/ml,
respectively) and late pregnancy (1.360.1 vs. 1.160.1 ng/ml and
64636 vs. 31623 pg/ml, respectively). There were no significant
changes in plasma cytokines and other biomarkers from early to
late pregnancy in either group of subjects.
T cell activation during and after pregnancy in HIV-
infected and uninfected women
Tact were primarily defined by the co-expression of CD38 and
HLADR or by cell surface expression of PD-1 on CD4+ or CD8+
Figure 1. Proportions of Treg in HIV-infected and uninfected women during early and late gestation. Bars represent means and
standard error of the mean (SEM) of data generated by flow cytometric analysis of freshly thawed PBMC. The Treg are expressed as a percentage of
the parent CD4+ or CD8+ T cell population. The graph titles indicate the Treg subpopulation depicted in each graph. Significant or marginally
significant differences between HIV-infected and uninfected women are indicated by p values immediately above each time point (Mann Whitney).
Horizontal lines indicate significant or marginally significant changes between early and late pregnancy. Such changes were detected only in
uninfected women.
doi:10.1371/journal.pone.0028172.g001
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CD38+HLADR+% compared with uninfected women in early
and late pregnancy (p of 0.04 and 0.002, respectively; Fig. 4) and
in CD8+CD38+HLADR+% in late pregnancy (p=0.002). There
were no significant differences in CD8+CD38+HLADR+%i n
early pregnancy or in PD-1 expression in early or late pregnancy
between HIV-infected and uninfected women.
Relationship of Treg with T cell function, activation and
inflammatory factors in HIV-infected and uninfected
women in early pregnancy
Correlation analyses were performed for each Treg% subpop-
ulation with CD4+CD38+HLADR+ and CD8+CD38+HLADR+
Tact%; VZV adjusted-cpm; and plasma inflammatory (neopterin
and IL8), Th1 (IFNc), Th2 (IL4) and regulatory (IL10) cytokine
concentrations (Table 2). VZV cpm showed significant negative
correlations with CD4+FoxP3+%, CD8+FoxP3+% and CD8+
TGFb+% (rho of 20.57 to 20.70; p of 0.004 to 0.03) and a trend
towards positive correlation with circulating CD4+CTLA4
+% (rho=0.49, p=0.07). Participants with higher CD4+CD25+
FoxP3+%, CD8+CD25+FoxP3+%, CD4+IL10+%, CD8+IL10+
%, CD4+TGFb+% and CD8+TGFb+% also had significant or
borderline significant higher plasma levels of neopterin, IL8, IFNc,
Figure 3. Inflammatory factors and other cytokines in HIV-infected and uninfected women during early and late gestation. Bars
represent means and SEM. The analytes are indicated in the graph titles. Significant differences between HIV-infected and uninfected women are
indicated by the p values immediately above the bars (Mann Whitney).
doi:10.1371/journal.pone.0028172.g003
Figure 2. Cell-mediated immunity in HIV-infected and unin-
fected pregnant women during early and late gestation. Data
were generated using VZV- and mock-stimulated cryopreserved PBMC.
Bars represent means and SEM of adjusted VZV-specific counts-per-
minute (cpm) after subtraction of mock-stimulated cpm. Significant
differences between HIV-infected and uninfected women at each time
point are indicated by the p values on the graph (unpaired T test using
log-transformed data).
doi:10.1371/journal.pone.0028172.g002
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marginally significant negative correlations of CD4+CD25+
FoxP3+% with CD4+CD38+HLADR+% and of CD4+TGFb+%
with CD8+CD38+HLADR+% (rho of 20.58 and 20.54; p of
0.08 and 0.1, respectively).
In uninfected pregnant women, Treg% were not associated with
CMI (Table 2). Higher CD8+CD25+FoxP3+% was marginally
associated with lower concentration of neopterin and higher
plasma concentrations of IL10, whereas CD4+CTLA4+% posi-
tively correlated with neopterin plasma levels. There were
significant or marginally significant negative correlations of
CD4+CD25+FoxP3+%, CD8+TGFb+% and CD4+FoxP3+%
Treg with CD4+CD38+HLADR+% and/or CD8+CD38+
HLADR+% Tact.
Figure 4. Proportions of Tact in HIV-infected and uninfected women during early and late gestation. Bars indicate mean and SEM
proportions of the Tact subpopulations indicated in the title of each graph. Tact are expressed as percentages of the parent CD4+ or CD8+ T cell
populations. Significant differences between HIV-infected and uninfected women are indicated by p values immediately above each time point
(Mann Whitney test).
doi:10.1371/journal.pone.0028172.g004
Table 2. Correlation of Treg with Cell-Mediated Immunity, Plasma Inflammatory Factors and Other Cytokines and Tact in HIV-
Infected and Uninfected Pregnant Women.
Variable (%) VZV Neopt IL8 IFNc IL4 IL10 CD4+ CD8+
cpm mg/ml pg/ml pg/ml pg/ml pg/ml act act
HIV-INFECTED WOMEN
CD4+CD25+FoxP3+ -0.19* 0.13 0.52 0.52 0.66 0.32 0.27 -0.58
CD8+CD25+FoxP3+ -0.08 0.45 0.50 0.51 0.31 0.48 0.14 -0.32
CD4+IL10+ 0.29 0.60 0.36 0.48 0.50 0.48 0 0.28
CD8+IL10+ -0.05 0.30 0.48 0.48 0.28 0.19 0.38 0.13
CD4+TGFb+ -0.17 0.20 0.18 0.08 0.22 0.60 -0.54 -0.03
CD8+TGFb+ -0.65 -0.03 0.58 0.39 0.40 0.36 -0.47 0.09
CD4+FoxP3+ -0.70 -0.13 0.32 0.18 0.04 0.09 -0.37 -0.10
CD8+FoxP3+ -0.57 -0.12 0.35 0.19 0.06 -0.06 -0.38 -0.09
CD4+CTLA4+ 0.49 0.21 0.11 0 0.19 0.08 0.05 0.07
CD8+CTLA4+ 0.22 0.22 0.23 0 0.27 -0.28 0.08 0.02
UNINFECTED WOMEN
CD4+CD25+FoxP3+ -0.16 0.19 -0.12 0 0.28 0.25 -0.69 0.01
CD8+CD25+FoxP3+ -0.12 -0.54 0.27 -0.10 0.35 0.52 -0.46 0.21
CD4+IL10+ -0.09 0.25 -0.22 0.45 -0.20 -0.14 0.28 0.20
CD8+IL10+ -0.03 0.10 -0.10 0.11 -0.06 0 -0.03 0
CD4+TGFb+ 0.12 0.06 0.31 -0.07 0.16 0.06 -0.35 0.30
CD8+TGFb+ -0.26 0.28 -0.23 -0.03 0.16 0.4 -0.58 0.09
CD4+FoxP3+ 0.20 0.11 0.35 -0.45 0.04 0.25 -0.67 -0.58
CD8+FoxP3+ -0.22 -0.10 0.11 0.08 0.17 0.07 -0.30 -0.09
CD4+CTLA4+ -0.17 0.59 0.08 0.24 0 0.21 0.02 -0.37
CD8+CTLA4+ 0.15 0.39 -0.08 0.17 -0.19 -0.07 0.14 -0.34
*Numbers represent Spearman correlation coefficients. Bold-facing and underscore indicates significant associations, with p,0.05; bold-facing and italics indicates
marginally significant associations with p values of 0.05 to 0.1.
doi:10.1371/journal.pone.0028172.t002
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common link for the associations of Treg with inflammatory
factors or with functional CMI described above, we performed
correlation analyses of HIV plasma RNA, CD4 cell numbers and
CD4% with each Treg subpopulation. These analyses revealed a
marginally significant association between CD4+FoxP3+% with
plasma HIV RNA (rho=0.53, p=0.07).
Discussion
In early pregnancy, CD4+ and CD8+ Treg subpopulations
were generally increased in HIV-infected compared with unin-
fected women. This included CD4+CD25+FoxP3+, CD8+CD25+
FoxP3+, CD4+TGFb+ and CD4+IL10+ Treg and it was most
likely an effect of HIV infection, which is in agreement with
previous findings in non-pregnant HIV-infected adults [6,8,44,45].
Our findings, however, contrast with a recently published study of
pregnant women, which showed lower CD4+CD25+FoxP3+C-
D127
low Treg frequencies in HIV-infected compared with
uninfected women during the 2nd trimester of pregnancy[46].
The duration of HAART of the HIV-infected subjects differed
between the two studies, with most of our subjects starting
HAART during pregnancy, while in the study by Kolte et al., most
subjects were on HAART before pregnancy. Since HAART has
been previously shown to decrease the frequency of circulating
Treg in HIV-infected individuals [47], the difference in the
duration of HAART may explain the difference between the two
study results.
More importantly, in late pregnancy several Treg subpopula-
tions, including CD4+CTLA4+%, CD8+CTLA4+% and
CD8+TGFb+% were lower in HIV-infected compared with
uninfected pregnant women, and only CD4+IL10+% remained
higher in HIV-infected women. Furthermore, no significant
increases in Treg% were detected in HIV-infected women
between early and late gestation, whereas in uninfected women,
we observed a marginally significant increase of CD8+CD25+
FoxP3+% and CD4+TGFb+% over the course of pregnancy.
Previous studies also observed Treg increases during normal
pregnancy and ascribed them a role in inducing maternal
tolerance of the fetus [48,49,50,51,52]. Blois et al. also determined
that CD8+ Treg had a pivotal role as a mediator of the anti-
abortogenic effect of progesterone in mice [53]. The lack of
Treg% upregulation during late gestation in HIV-infected
pregnant women may lead to a premature loss of fetal tolerance
and premature delivery. In fact, HIV-infected women have a
higher incidence of premature delivery compared with the general
population [54,55,56]. This was sometimes, but not always,
correlated with the use of protease inhibitor-containing HAART
[56,57]. It is conceivable that the use of HAART may exert a
downregulatory pressure on Treg subpopulations similar to what
was described in non-pregnant HIV-infected adults [47]. Further-
more, we found an association, albeit weak, between plasma HIV
load and CD4+FoxP3+% in early pregnancy, which also supports
the notion that active HIV replication may increase Treg%, while
HAART-mediated control of HIV replication may have the
opposite effect. The hypothesis that lack of upregulation of specific
Treg subpopulations in late pregnancy is associated with
premature delivery needs to be further confirmed in larger studies,
because it may lead to new therapeutic interventions.
To gather information on the Treg functionality, we studied the
relationship of Treg% with VZV-specific lymphocyte prolifera-
tion. We chose VZV CMI as a representative measure because of
the high prevalence of VZV infection in the US adult population
(.90%) and the well-demonstrated role of VZV CMI in
protection against VZV reactivation and herpes zoster [58,59].
We found that higher CD4+FoxP3+%, CD8+FoxP3+% and
CD8+TGFb+% were significantly associated with lower VZV-
specific proliferation in HIV-infected pregnant women. Interest-
ingly, not all Treg subpopulations were associated with decreased
CMI in HIV-infected pregnant women, which suggests different
specificities of Treg subpopulations. Furthermore, Treg% were not
associated with lower CMI in HIV-uninfected pregnant women. It
is possible that the association between high Treg% and low CMI
in the context of HIV infection is indirect and that both
phenomena are linked to active HIV replication. However, it is
also conceivable that the higher frequency of Treg in HIV-infected
women during early pregnancy allowed us to detect an inhibitory
effect on CMI only in this group of participants. This may be due
to a higher ratio between Treg and effector memory T cells in
HIV-infected compared with uninfected women and/or broader
antigen specificity of certain CD4+FoxP3+, CD8+FoxP3+ and
CD8+ TGFb+ Treg in HIV-infected women.
Among the Treg markers used in this study, CTLA4 seemed to
behave differently from others. CD4+CTLA4+% and
CD8+CTLA4+% were higher in HIV-uninfected compared with
infected pregnant women and this difference reached statistical
significance in late pregnancy, whereas most other Treg% were
higher in HIV-infected women in early pregnancy. Furthermore,
soluble CTLA4 plasma concentrations were significantly higher in
HIV-uninfected women both in early and late gestation, whereas
IL10 plasma concentrations were higher in HIV-infected women.
CTLA4 is expressed both by Treg and memory effector T cells
and in both circumstances contributes to down-modulation of the
cellular immune response. Memory effector T cells quickly
upregulate CTLA4 expression upon cognate antigenic stimulation.
Binding of CD80 or CD86 ligands to CTLA4 on effector memory
T cells decreases their IL2 production and cell cycle progression
[60]. In counterpart, CTLA4 expression on Treg allows them to
block the activation of naı ¨ve T cells. In this study, we did not
differentiate between effector memory and Treg expression of
CTLA4 [61]. It is conceivable that some of the CTLA4+ T cells
measured in this study were effector memory cells expressing
CTLA4, which may explain the different dynamics of CTLA4+ T
cells compared with other Treg subpopulations. Conversely,
CTLA4+ T cells may represent bonafide Treg and their behavior
in pregnancy differs from that of other Treg subpopulations.
Further studies are needed to elucidate the role of CTLA4
expression in maintenance of pregnancy and the potential role that
CTLA4Ig might play as a therapeutic intervention.
We found that HIV-infected women had elevated
CD4+CD38+HLADR+% and CD8+CD38+HLADR+% Tact
compared with uninfected women, which was in agreement with
previous observations in non-pregnant individuals [34]. Insuffi-
cient T cell regulation was invoked as a potential contributor to
high levels of T cell activation in HIV-infected individuals [13,15].
In this study, we found negative associations between Treg% and
Tact%, which reached statistical significance in uninfected
pregnant women and were only marginally significant in HIV-
infected participants. This is unlikely to be due to deficient Treg
function in the context of HIV infection, because we also observed
a strong negative association between Treg% and lymphocyte
proliferation in HIV-infected women. A more likely explanation is
that in the context of HIV infection Treg and Tact share some of
the pathophysiologic mechanisms, partially masking the inhibitory
Treg effect on Tact. This would be in agreement with the model
proposed by Boasso et al. whereby activation of plasmacytoid
dendritic cells by HIV infection would increase both regulation
and activation [62].
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Treg cytokines were consistently higher throughout pregnancy in
HIV-infected compared with uninfected pregnant women. High
levels of inflammatory factors in non-pregnant HIV-infected adults
were previously shown to correlate with increased risk of non-
AIDS severe adverse events, such as cardiovascular, hepatic and
renal dysfunctions [63]. In pregnancy, high inflammatory factors
may lead to obstetric morbid conditions, such as premature
delivery, pre-eclampsia and liver disorders [38,64,65,66]. In HIV-
infected pregnant women, like in other HIV-infected non-
pregnant adults [8,9], inflammatory factors, Th1, Th2 and Treg
cytokines were positively correlated with Treg%, probably
reflecting a common pathophysiologic mechanism. However, in
uninfected pregnant women, CD8+FoxP3+% were negatively
associated with inflammatory markers and positively associated
with Treg cytokines signaling that Treg interactions may differ
between HIV-infected and uninfected pregnant women. It is
important to confirm these findings and further characterize Treg
subpopulations and inflammatory factors that play a direct role in
the outcome of pregnancies, which may provide new avenues for
therapeutic interventions.
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